Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pan-tumor × Oxaliplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 398 Stomach Neoplasms 271 Rectal Neoplasms 248 Colonic Neoplasms 181 Pancreatic Neoplasms 155 Neoplasm Metastasis 96 Esophageal Neoplasms 81 Neoplasms 62 Carcinoma, Hepatocellular 54 Adenocarcinoma Of Esophagus 43 Adenocarcinoma 42 Lymphoma, Large B-Cell, Diffuse 41 Cholangiocarcinoma 40 Carcinoma, Non-Small-Cell Lung 36 Biliary Tract Neoplasms 31 Gallbladder Neoplasms 27 Liver Neoplasms 25 Gastrointestinal Neoplasms 25 Recurrence 24 Esophageal Squamous Cell Carcinoma 21 Breast Neoplasms 21 Ovarian Neoplasms 19 Bile Duct Neoplasms 17 Peritoneal Neoplasms 16 Unspecified Adult Solid Tumor, Protocol Specific 15 Appendiceal Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Lymphoma, Non-Hodgkin 10 Lung Neoplasms 10 Locally Advanced Rectal Cancer 10

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡